These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11553167)

  • 1. Cutaneous hyperpigmentation following venous sclerotherapy treated with deferoxamine mesylate.
    Lopez L; Dilley RB; Henriquez JA
    Dermatol Surg; 2001 Sep; 27(9):795-8. PubMed ID: 11553167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing hyperpigmentation after sclerotherapy: A randomized clinical trial.
    Gonzalez Ochoa AJ; Carrillo J; Manríquez D; Manrique F; Vazquez AN
    J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):154-162. PubMed ID: 32739509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia].
    Bogachev VI; Boldin BV; Turkin PI; Lobanov VN
    Angiol Sosud Khir; 2019; 25(4):102-107. PubMed ID: 31855206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of sclerotherapy.
    Munavalli GS; Weiss RA
    Semin Cutan Med Surg; 2007 Mar; 26(1):22-8. PubMed ID: 17349559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome.
    Weiss RA; Sadick NS; Goldman MP; Weiss MA
    Dermatol Surg; 1999 Feb; 25(2):105-8. PubMed ID: 10037513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial.
    Scultetus AH; Villavicencio JL; Kao TC; Gillespie DL; Ketron GD; Iafrati MD; Pikoulis E; Eifert S
    J Vasc Surg; 2003 Nov; 38(5):896-903. PubMed ID: 14603191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerotherapy in tumescent anesthesia of reticular veins and telangiectasias.
    Ramelet AA
    Dermatol Surg; 2012 May; 38(5):748-51. PubMed ID: 22268802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol.
    Weiss RA; Weiss MA
    J Dermatol Surg Oncol; 1990 Sep; 16(9):800-4. PubMed ID: 2398199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.
    Bossart S; Daneluzzi C; Cazzaniga S; Ramelet AA; Uthoff H; Seyed Jafari SM; Baumgartner M; Hunger RE; Heidemeyer K; Willenberg T
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):274-283. PubMed ID: 36196455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Q-switched ruby laser treatment for postsclerotherapy hyperpigmentation.
    Tafazzoli A; Rostan EF; Goldman MP
    Dermatol Surg; 2000 Jul; 26(7):653-6. PubMed ID: 10886273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Telangiectasias associated with reticular veins. Sclerotherapy or combined sclerotherapeutic and surgical approach?].
    Albanese V; Cavallaro G
    Minerva Cardioangiol; 2002 Feb; 50(1):29-37. PubMed ID: 11830716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review.
    Willenberg T; Smith PC; Shepherd A; Davies AH
    Phlebology; 2013 Apr; 28(3):123-31. PubMed ID: 23761921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerotherapy for varicose and telangiectatic veins.
    Green D
    Am Fam Physician; 1992 Sep; 46(3):827-37. PubMed ID: 1514476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postsclerotherapy hyperpigmentations. Chromated glycerin as a screen for patients at risk (a retrospective study).
    Georgiev M
    J Dermatol Surg Oncol; 1993 Jul; 19(7):649-52. PubMed ID: 8349903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sclerotherapy in abnormal varicose hand veins.
    Duffy DM; Garcia C; Clark RE
    Plast Reconstr Surg; 1999 Oct; 104(5):1474-9; discussion 1480-1. PubMed ID: 10513934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cryocompression sclerotherapy of reticular veins and teleangiectasias].
    Bogachev VI; Kuznetsov MR; Lobanov VN; Turkin PI
    Angiol Sosud Khir; 2018; 24(3):92-97. PubMed ID: 30321152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1.
    Bogachev VY; Boldin BV; Turkin PY
    Adv Ther; 2018 Jul; 35(7):1001-1008. PubMed ID: 29949043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose Veins.
    Yiannakopoulou E
    Pharmacology; 2016; 98(1-2):62-9. PubMed ID: 27104778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins.
    Kern P; Ramelet AA; Wutschert R; Mazzolai L
    Dermatol Surg; 2011 Nov; 37(11):1590-4. PubMed ID: 21883648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "Sclerotherapy in tumescent anesthesia of reticular veins and telangiectasias".
    Raymond-Martimbeau P
    Dermatol Surg; 2012 May; 38(5):752-3. PubMed ID: 22563653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.